Spectral Medical Inc. is a Canada-based late-stage theranostic company focused on advancing therapeutic solutions for sepsis and septic shock. The Company develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The Company also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. It provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.